While the value of national arthroplasty registries (NAR) for quality improvement in total hip arthroplasty (THA) has already been widely reported, some methodological limitations associated with observational epidemiological studies that may interfere with the assessment of safety and efficacy of prosthetic implants have recently been described in the literature.Among the main limitations of NAR, the need for at least 80% compliance of all health institutions covered by the registry is emphasized; completeness equal or greater than 90% of all THA performed; restricted data collection; use of revision surgery as the sole criterion for outcome; and the inability of establishing a definite causal link with prosthetic dysfunction.The present article evaluates the advantages and limitations of NAR, in the light of current knowledge, which point to the need for a broader data collection and the use of more structured criteria for defining outcomes.In this scenario, the authors describe of idealization, conceptual and operational structure, and the project of implantation and implementation of a multicenter registry model, called Rempro-SBQ, which includes healthcare institutions already linked to the Brazilian Hip Society (Sociedade Brasileira de Quadril [SBQ]). This partnership enables the collection of more reliable and comprehensive data at a higher hierarchical level, with a significant reduction in maintenance and financing costs. The quality improvement actions supported by SBQ may enhance its effectiveness and stimulate greater adherence for collecting, storing, interpreting, and disseminating information (feedback).
ObjectiveTo radiographically evaluate the quality of cementation and implantation technique using a polished, triple-tapered femoral stem in total hip arthroplasty (THA).MethodRetrospective study with radiographic evaluation of 86 hips in 83 patients who underwent to primary THA with the triple-tapered cemented femoral stem C-Stem (DePuy Orthopedics, Warsaw, Indiana). Cases with at least one-year of follow-up were included, and data related to preoperative, immediate postoperative, and late postoperative radiographic evolution were recorded. This study analyzed, among others, the proximal femoral anatomy, the quality of cementation as described by Barrack, and the implant positioning. Cementation was also evaluated and quantified in the Gruen zones with one-year of follow-up.ResultsThe mean age was 62.85 years. Proximal femoral anatomical conformation was Dorr type A in 34 (39.53%) cases, type B in 52 (60.46%), and no type C cases were found. Five (5.81%) cases were defined as type A by Barrack's cementation classification system, 46 (56.49%) type B, 27 (31.40%) type C, and eight (9.30%) type D. The greatest cement mantle thickness was observed in zones four (15.53 mm) and 11 (15.64 mm), and the smallest in zone nine (3.51 mm). Positioning in varus was observed in eight (9.3%) cases, valgus in 25 (29%), forward deviation in two (5%), and backward deviation in 55 (63.95%).ConclusionsThe C-Stem femoral system presented satisfactory results related to cementation pattern, positioning, osteolysis, and stress shielding with regard to literature referring to double-tapered or triple-tapered models, demonstrating to be a safe method, with a predictable and reliable cementing pattern.
ResumoA epifisiólise capital femoral proximal (ECFP) pode resultar em impacto femoroacetabular (IFA) do quadril em até um terço dos casos. A deformidade residual em came ou “cabo de pistola” está associada a lesão condrolabral, resultando em dor, incapacidade funcional, e osteoartrose precoce. O tratamento artroscópico com osteocondroplastia mostrou-se benéfico em um caso selecionado de IFA secundário a ECFP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.